A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome

• ClinicalTrials.gov Identifier: NCT02829268
• Recruitment Status: Recruiting
• First Posted: July 12, 2016
• Last Update Posted: May 14, 2019
• Sponsor: Washington University School of Medicine
• Collaborator: National Institutes of Health (NIH)
• Information provided by (Responsible Party): Washington University School of Medicine

Tracking Information

• First Submitted Date: July 6, 2016
• First Posted Date: July 12, 2016
• Last Update Posted Date: May 14, 2019
• Actual Study Start Date: January 2017
• Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 30, 2018)

Number of participants with treatment-related adverse events as assessed by liver function tests [ Time Frame: 6 months with an optional extension phase up to 24 months ]

The investigators assess the safety and tolerability of dantrolene sodium administered orally at upper end of therapeutic dose range for 6 months in patients with Wolfram syndrome. More specifically, the investigators perform liver function tests to check the levels of certain enzymes and proteins in participants' blood. Levels that are higher or lower than normal can indicate liver problems. The liver function tests include: Alanine transaminase (ALT), Aspartate transaminase (AST), Alkaline Phosphatase (AP), and bilirubin.

Original Primary Outcome Measures (submitted: July 7, 2016)

Number of participants with treatment-related adverse events as assessed by liver function tests [ Time Frame: 6 months ]

The investigators assess the safety and tolerability of dantrolene sodium administered orally at upper end of therapeutic dose range for 6 months in patients with Wolfram syndrome. More specifically, the investigators perform liver function tests to check the levels of certain enzymes and proteins in participants' blood. Levels that are higher or lower than normal can indicate liver problems. The liver function tests include: Alanine transaminase (ALT) and Aspartate transaminase (AST).

• Change History: Complete list of historical versions of study NCT02829268 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures (submitted: April 30, 2018)

• Changes in C-peptide levels in participants assessed by the ELISA assay [ Time Frame: 6 months with an optional extension phase up to 24 months ]
  The investigators determine the effect of dantrolene sodium on residual beta cell functions. The investigators monitor base-line C-peptide levels in participants' blood. The investigators also monitor C-peptide levels in participant's blood during the oral mixed meal tolerance test. The night before the oral mixed meal tolerance test, the participants will turn their insulin pump basal rate to 50% of the normal rate at midnight or take half of their evening dose of Lantus insulin and fasted from midnight until the test at 8 a.m. The mixed meal consists of 6 ml/kg (maximum 360 ml) of Boost Original (Société des Produits Nestlé S.A., Vevey, Switzerland). Blood for glucose and C-peptide measurement will be drawn at time 0 (fasting) and 30 minutes after the Boost. If a subject's fasting glucose exceeds 11.1 mmol/l, the test will not be performed, but fasting glucose and C-peptide will be obtained.
• Changes in Visual Functioning in participants assessed by Visual Functioning Questionnaire-25. [ Time Frame: 6 months with an optional extension phase up to 24 months ]
  Visual functions will be assessed by Visual Functioning Questionnaire - 25.
• Changes in best-corrected visual acuity in participants measured by Snellen optotype [ Time Frame: 6 months with an optional extension phase up to 24 months ]
  Best-corrected visual acuity will be measured by Snellen optotype. Higher logMar scores indicate worse vision.
• Changes in Neurological Functions in participants assessed by the Wolfram Unified Rating Scale (WURS) [ Time Frame: 6 months with an optional extension phase up to 24 months ]
  Neurological functions will be assessed by the Wolfram Unified Rating Scale (WURS) and standard neurological assessments.

Original Secondary Outcome Measures (submitted: July 7, 2016)

• Changes in C-peptide levels in participants assessed by the ELISA assay [ Time Frame: 6 months ]
  The investigators determine the effect of dantrolene sodium on residual beta cell functions. The investigators monitor base-line C-peptide levels in participants' blood. The investigators also monitor C-peptide levels in participant's blood during the oral mixed meal tolerance test. The night before the oral mixed meal tolerance test, the participants will turn their insulin pump basal rate to 50% of the normal rate at midnight or take half of their evening dose of Lantus insulin and fasted from midnight until the test at 8 a.m. The mixed meal consists of 6 ml/kg (maximum 360 ml) of Boost Original (Société des Produits Nestlé S.A., Vevey, Switzerland). Blood for glucose and C-peptide measurement will be drawn at time 0 (fasting) and 30 minutes after the Boost. If a subject's fasting glucose exceeds 11.1 mmol/l, the test will not be performed, but fasting glucose and C-peptide will be obtained.
• Changes in dynamic balance in participants assessed by the Mini-Balance Evaluation Systems Test (Mini BESTest) [ Time Frame: 6 months ]
  Balance will be measured by the Mini-Balance Evaluation Systems Test (Mini BESTest). The Mini BESTest is a clinician rated assessment of dynamic balance. Lower scores are indicative of impairments in balance. The total possible score on this evaluation is 28, indicating no balance impairmen
• Changes in best-corrected visual acuity in participants measured by Snellen optotype [ Time Frame: 6 months ]
  Best-corrected visual acuity will be measured by Snellen optotype. Higher logMar scores indicate worse vision)

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome
• Official Title: A Phase 1b Safety Trial of Dantronele Sodium in Pediatric and Adult Patients With Wolfram Syndrome

Brief Summary

Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.

There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: Non-Randomized; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Wolfram Syndrome
• Diabetes Mellitus
• Optic Nerve Atrophy
• Ataxia

Intervention

Drug: dantrolene sodium

The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.

There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.

Study Arms

• Experimental: Pediatric
  Pediatric patients treated with dantrolene sodium
  Intervention: Drug: dantrolene sodium
• Experimental: Adult
  Adult patients treated with dantrolene sodium
  Intervention: Drug: dantrolene sodium

• Publications *: Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. Curr Diab Rep. 2016 Jan;16(1):6. doi: 10.1007/s11892-015-0702-6. Review.

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: March 13, 2017): 50
• Original Estimated Enrollment (submitted: July 7, 2016): 25
• Estimated Study Completion Date: March 2021
• Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

Patients must meet all of the following criteria to be eligible for enrolment:

1. The patient has a definitive diagnosis of Wolfram syndrome, as determined by the following:

   a. Documented functionally relevant recessive mutations on both alleles of the WFS1 gene or dominant mutation on one allele of the WFS1 gene based on historical test results (if available) or from a qualified laboratory at screening.

2. The patient is at least 5 years of age (biological age) at the time of written informed consent.
3. The patient, patient's parent(s), or legally authorized guardian(s) must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient. The guardians' consent and patient's assent, as relevant, must be obtained.

Exclusion Criteria:

Patients who meet any of the following criteria are not eligible for this study:

1. The patient has clinically significant non-Wolfram related CNS involvement which is judged by the investigator to be likely to interfere with the accurate administration and interpretation of protocol assessments.
2. The patient has a known defect in oxidative phosphorylation (such as a confirmed mitochondrial myopathy)
3. The patient has abnormal liver function (defined as serum transaminases more than twice the upper limit of normal for the reference laboratory)
4. The patient has a significant medical or psychiatric co-morbidity that might affect study data or confound the integrity of study results.
5. The patient has received treatment with any investigational drug within the 30 days prior to study entry.
6. The patient has received blood product transfusions within 90 days prior to screening.
7. The patient is unable to comply with the protocol, (e.g. has a clinically relevant medical condition making implementation of the protocol difficult, unstable social situation, known clinically significant psychiatric/behavioural instability, is unable to return for safety evaluations, or is otherwise unlikely to complete the study), as determined by the Investigator.
8. The patient has a known history of central apnea and/or ventilation requirements.
9. The patient has a known history of chronic obstructive pulmonary disease, pleural effusion, and/or myocardial disease.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 5 Years to 60 Years (Child, Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Ashley N Simpson, RN, BSN, CPN; +1-314-286-1550; ashley.simpson@wustl.edu

Contact: Teresa Arb, RN, BSN, CCRC; +1-314-747-1217; arbt@wustl.edu

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02829268
• Other Study ID Numbers: 201607006
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: Yes
• Plan Description: publication

• Responsible Party: Washington University School of Medicine
• Study Sponsor: Washington University School of Medicine
• Collaborators: National Institutes of Health (NIH)

Investigators

• Study Director: Fumihiko Urano, MD; Washington University School of Medicine

• PRS Account: Washington University School of Medicine
• Verification Date: May 2019